Healthcare entity
Boston Scientific is most often covered alongside Medtronic, which appears in 2 of these 3 stories. health-it accounts for 2 of the 3 tracked stories, while 1 other category carries the remainder. Each story carries 4.7 original sources on average, compared with 3.5 for the broader beat in this window.
Last mentioned: Sep 2, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 34 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Boston Scientific is most often covered alongside Medtronic, which appears in 2 of these 3 stories. health-it accounts for 2 of the 3 tracked stories, while 1 other category carries the remainder. Each story carries 4.7 original sources on average, compared with 3.5 for the broader beat in this window. Across a 175-day span, the pace is roughly 0.1 stories per week. Their average consequence score of 6.7 runs above the beat's 6 for that window. Boston Scientific appears in 3 tracked Healthcare stories published from March 12, 2026 through September 2, 2026.
Computed from the 3 stories linked to this entity, with beat comparisons drawn from all 887 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Boston Scientific. Shared-story counts are live from our verified record — not editorial picks.
NXT 41X Launch
Anticipated commercial launch of Elutia's next-gen drug-eluting biomaterial.
Public breach disclosure
Novocure publicly reported the cyberattack, disclosing that internal records of more than 1,400 U.S. patients were exposed.
Unauthorized access occurs
Novocure says unauthorized access to certain information systems occurred in mid-August 2026, exposing internal patient records.
Incident response activated
Novocure activated its cybersecurity response plan, implemented containment measures, and initiated an internal investigation.
Bumble 2.0 Launch
Targeted launch of AI-enabled platform experience.
Codexis CDMO Expansion
Announced three major CDMO agreements with Bachem, Nitto Avecia, and Axolabs.
Elutia FDA Milestone
Expected FDA submission for NXT 41X product line.
Elutia Divestiture
Completed $88M sale of bioenvelope business to Boston Scientific.
Novocure disclosed a mid-August cyberattack that exposed internal records of more than 1,400 U.S. oncology patients, along with provider contact details and employee job titles. The company said treatment devices were not accessed and that it expects no material financial impact. For healthcare IT and compliance leaders, the incident is another compelling case study in breach response, data classification, and regulatory risk.
Source: CNA
A cybersecurity incident at Boston Scientific has disrupted order processing and shipping globally, threatening hospitals and surgical centers reliant on its devices. Analysts warn of a 600-700 bps Q3 revenue hit if recovery matches Stryker's three-week timeline. Health leaders must assess supply chain and patient care risks.
Source: CNA · Sahil Pandey
The Q4 2025 earnings cycle for mid-cap healthcare and life sciences firms reveals a strategic shift toward high-margin AI integration and portfolio streamlining. Companies like Elutia and Codexis are leveraging divestitures and technology transfers to shore up balance sheets, while AI-driven productivity gains are becoming a primary differentiator in clinical and operational workflows.
Boston Scientific is linked from 3 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
